Current Report Filing (8-k)
June 15 2020 - 6:18AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 14, 2020
ENDOLOGIX, INC.
(Exact
Name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware
|
|
000-28440
|
|
68-0328265
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
2 Musick
Irvine, CA 92618
(Address
of Principal Executive Office) (Zip Code)
Registrants telephone number, including area code:
(949) 595-7200
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2 below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, par value $0.001 per share
|
|
ELGX
|
|
The Nasdaq Stock Market, LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 1.01
|
Entry into a Material Definitive Agreement
|
On June 14, 2020, Endologix, Inc. (the Company) entered into Amendment No. 1 (the ABL Forbearance Amendment) to Forbearance
Agreement (the ABL Forbearance Agreement) to Credit Agreement, dated as of August 9, 2018 (as amended, restated, supplemented or otherwise modified from time to time, the Credit Agreement), with the Lenders party thereto
from time to time, and Deerfield ELGX Revolver, LLC, as agent for itself (the ABL Agent) and the Lenders (collectively, the ABL Forbearing Parties). Additionally, on June 14, 2020, the Company entered into Amendment
No. 1 (the Facility Forbearance Amendment and, collectively with the ABL Forbearance Amendment, the Forbearance Amendments) to Forbearance Agreement (the Facility Forbearance Agreement and, collectively with
the ABL Forbearance Agreement, the Forbearance Agreements) to Amended and Restated Facility Agreement, dated as of August 9, 2018 (as amended, restated, supplemented or otherwise modified from time to time, the Facility
Agreement), with the Lenders party thereto from time to time, and Deerfield Private Design Fund I.V., L.P. as agent for itself (together with the ABL Agent, Deerfield) and the Lenders (collectively, the Facility Forbearing
Parties and, collectively with the ABL Forbearing Parties, the Forbearing Parties).
The Forbearance Amendments extend the termination date of
the forbearance period provided for in the Forbearance Agreements from June 15, 2020 to June 30, 2020. The Forbearance Amendments also require that the Company cause an individual designated by Deerfield to be appointed to the
Companys Board of Directors, in addition to other obligations imposed on the Company.
The foregoing descriptions of the ABL Forbearance Amendment
and the Facility Forbearance Amendment are not complete and are qualified in their entirety by reference to the full text of such documents, copies of which will be filed with the Companys next Quarterly Report on Form 10-Q in accordance with the rules and regulations of the Securities and Exchange Commission.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Endologix, Inc.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Vaseem Mahboob
|
June 15, 2020
|
|
|
|
|
|
Vaseem Mahboob
|
|
|
|
|
|
|
Chief Financial Officer
|
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Sep 2023 to Sep 2024